Articles tagged with: Dexamethasone
News»

Results of a small, Phase 1/2 Australian study indicate that a combination of Istodax, Velcade, and dexamethasone may be effective in relapsed and refractory multiple myeloma patients.
According to the study authors, patients who participated in the study achieved durable responses and experienced manageable treatment-related side effects with the Istodax combination treatment.
Based on their findings, the study authors concluded that the Istodax combination treatment warrants further evaluation.
“We continue to examine this combination on a [21-day] schedule. We are also planning a study of Revlimid and [Istodax] in a number of …
News»

Newly diagnosed, high-risk multiple myeloma patients can be effectively treated with sequential therapy, according to the results of a recent Phase 2 study. Participants in this study initially received a combination of Velcade, Doxil, and dexamethasone followed by a combination of thalidomide and dexamethasone, with the potential addition of Velcade to the second phase.
The study authors found that the sequential treatment provided rapid responses, which they said is crucial for patients with organ damage or those with advanced disease who need to quickly proceed to stem cell transplantation.
They suggested that …
NewsFlash »
Reduced-Dose Velcade-Thalidomide-Dexamethasone Is Effective For Newly Diagnosed Myeloma – Recently published results from a French study show that the combination of reduced-dose Velcade (bortezomib) and thalidomide (Thalomid) plus dexamethasone (Decadron) is safer and more effective than standard-dose Velcade plus dexamethasone for the treatment of newly diagnosed multiple myeloma patients. The results were previously presented at the American Society of Clinical Oncology (ASCO) meeting in June 2010. Results showed that after four cycles of therapy, patients who received the reduced-dose three-drug combination had a significantly higher response rate and experienced fewer side effects than patients receiving the standard-dose regimen. The same group of patients continued to have a higher response rate after stem cell transplantation. For a more detailed summary of the results, please see the Beacon’s coverage of the ASCO presentation or the study in the journal Blood (abstract).
Phase 3 Clinical Trial Investigating The Need For Stem Cell Transplantation Is Recruiting Myeloma Patients – Newly diagnosed multiple myeloma patients under the age of 65 years are being recruited at various cancer centers across the United States for a Phase 3 clinical trial that will investigate whether stem cell transplants are necessary in the era of novel agents. All participants will be treated with a combination of Revlimid (lenalidomide), Velcade, and dexamethasone. Half of the patients will then also receive a stem cell transplant. Based on the results, researchers will determine whether stem cell transplantation significantly extends progression-free survival. For more information or to enroll, please see the clinical trial description.
Teleconference On Clinical Trial Participation – On Thursday, the International Myeloma Foundation will sponsor a teleconference about the importance of participating in clinical trials. Dr. Brian Durie, a myeloma specialist at Cedars-Sinai Cancer Center, will discuss the Phase 3 clinical trial comparing carfilzomib-Revlimid-dexamethasone and Revlimid-dexamethasone alone. The call will be held from 4 p.m. to 5 p.m. PT. For more information, please see the International Myeloma Foundation website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News»

The results of a recent Phase 2 trial show that the addition of cyclophosphamide to Revlimid and low-dose dexamethasone may result in better responses for previously untreated myeloma patients.
“This [study] provides the efficacy of another regimen for use in patients with myeloma,” said the study’s lead author Dr. Shaji Kumar of the Mayo Clinic in Rochester, Minnesota. “It is a fairly safe combination and is quite efficacious,” he stated in an e-mail to The Myeloma Beacon.
According to the study authors, the combination of Revlimid (lenalidomide), cyclophosphamide (Cytoxan) and …
News»

Results of a recent study conducted in the United Kingdom show that elderly and transplant-ineligible multiple myeloma patients who are treated with a reduced-dose combination of cyclophosphamide, thalidomide, and dexamethasone as initial therapy achieve a greater overall response rate than patients who are treated with melphalan plus prednisone.
However, patients who received the three-drug combination had comparable overall survival and progression-free survival rates as patients who received melphalan plus prednisone. Additionally, side effects were more common among patients treated with the three-drug combination.
High-dose chemotherapy followed by autologous stem cell transplantation is …
News»

Results of a recent Italian study suggest that a combination of Velcade and dexamethasone is a safe and effective form of maintenance therapy for relapsed/refractory multiple myeloma patients who responded to Velcade-containing rescue regimens.
“Our study showed that maintenance therapy with Velcade in relapsed / refractory multiple myeloma patients may improve the progression-free survival and overall survival of patients with a low grade of toxicity,” Dr. Giulia Benevolo, lead author of the study, told The Myeloma Beacon.
“[However], this is a Phase 2 trial, and the results must be confirmed in randomized …
News»

A group of Italian researchers recently showed that consolidation therapy with Velcade, thalidomide, and dexamethasone was more effective than consolidation therapy with thalidomide and dexamethasone alone.
In particular, they found that the Velcade-based consolidation therapy yielded more high-quality responses, such as complete responses, and a high rate of molecular remission, in which patients showed no signs of remaining myeloma cells.
Dr. Michele Cavo from the Seragnoli Institute of Hematology in Bologna, Italy, presented the results at the 16th Congress of the European Hematology Association (EHA) in London last week.
In the study, …